$Rezolute (RZLT.US)$ NEWS (Late) Rezolute Reports Positive T...
NEWS (Late)
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
Rezolute announced positive topline results from its Phase 2 study of RZ402 in Diabetic Macular Edema (DME) patients. The study met primary endpoints, showing a significant reduction in central subfield thickness (CST) and a good safety profile. This is the first oral therapy to demonstrate such effects, highlighting potential for early disease intervention. The study involved 94 participants and evaluated three dosages over 12 weeks. Results indicated a significant improvement in CST, especially at the 200 mg dose, with no severe adverse effects related to the drug. A virtual investor event will be held today at 5:30 pm ET to discuss these findings.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Qocktail : I really appreciate your news my man I subbed to see what you find interesting